中文摘要：

目的 探讨2型糖尿病病人（type 2 diabetes mellitus,T2DM）合并大血管病变的危险因素以及危险因素之间的交互作用。方法 设计调查问卷,收集1999年1月~2010年12月期间在广州市某医院住院的2型糖尿病患者的病历资料,包括年龄、性别、病程等19个变量。采用分类树对危险因素进行定性的交互作用分析,采用非条件Logistic回归模型定量分析危险因素的交互作用效应。结果 单纯T2DM无并发症的患者595例,T2DM合并大血管病变754例。建立分类树模型,包括3层,7个结点,4个终末节点,筛选出年龄、总胆固醇（total cholesterol,TC）、病程、高密度脂蛋白（high-density lipoprotein,HDL）、TC/HDL、三酰甘油（triacylglycerol,TG）、低密度脂蛋白（low density lipoprotein,LDL）、体重指数（body mass index,BMI）共8个危险因素。而与2型糖尿病大血管病变关联最密切的是年龄、病程和BMI。非条件Logistic回归分析结果显示：年龄与病程（OR=6.215,95%CI：2.867~13.476,P〈0.001）、年龄与BMI（OR=2.484,95%CI：1.465~4.212,P=0.001）在2型糖尿病进展大血管病变中存在交互作用。结论 年龄、病程和BMI相互作用是T2DM合并大血管病变的重要危险因素,年龄超过56岁,病程超过10年的患者应重点监测和干预,以防止大血管病变的发生。

英文摘要：

Objective To explore the risk factors of the type 2 diabetes mellitus （T2DM） with macrovascular complications and their interactions. Methods Type 2 diabetes patients＇ records were collected by questionnaires in some hospital in Guangzhou during 1999-2010, including age, gender and course of disease, etc. The interactions between risk factors were analyzed by classification tree and logistic regression models. Results 595 T2DM subjects showed no complications and 754 patients suffered from macrovascular complications. The classification tree models showed that there were three layers, seven nodes, and four terminal nodes, in which age, total cholesterol （ TC ） , course of disease, TC / HDL, high-density lipoprotein（ HDL）, triacylglycerol （TG）, low density lipoprotein （LDL）, and body mass index （BMI） were found to be risk factors. Moreover, age, course of disease and BMI were most closely related to T2DM with macrovascular complications. There were interactions between age and course of disease （ OR = 6. 215,95% CI： 2. 867-13.476, P 〈 0.001 ）, as well as age and BMI （ OR = 2. 484,95 % CI： 1. 465-4. 212, P = 0. 001 ）. Conclusions There are interactions between age and course of disease, age and BMI in the progression of type 2 diabetes macrevascular complications. Those patients who are over 56 and the course of disease over 10 years should be given key monitoring intervention to control macreangiopathy progression.